New tools against cancer thanks to funding from La Marató
El Punt Avui, La Razón, El Periódico, El Economista, among other media, have published an article about the research that was financed with the 12 million euros collected in TV3’s 2012 Marató (telethon) dedicated to cancer. La Marató has highlighted, among others, two IRB Barcelona projects that were awarded funding. On the one hand, Núria López-Bigas developed the "Cancer Genome Interpreter", a platform that allows better selection of treatments for cancer and the prediction of patient response. And on the other, Salvador Aznar Benitah led a project addressing metastasis and its relation to the consumption of dietary fat.
Link to El Periódico
Link to El Economista
Related content
News
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
Published in the journal Nature Cancer, the study analyses how genetic alterations in tumour cells prevent the correct degradation of the proteins involved in tumour development and growth, thereby leading to abnormal cell behaviour.
A machine-learning model has allowed the scientists to obtain the most extensive annotation of the ubiquitin-mediated protein degradation system.
The analysis proposes a potential new clinical approach for cancer through the inhibition of oncoproteins with impaired degradation systems.
The newspaper La Tribuna de Albacete has interviewed IRB Barcelona researcher Erika López Arribillaga about a grant awarded to her on 24 September by the Spanish Association Against Cancer (AECC). López Arribillaga’s project aims to unravel the long-term effects of some chemotherapy treatments on colorectal cancer patients.
Link to La Tribuna de Albacete
